KALA BIO, Inc. — Director's Dealing 2020

Apr 13, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2020-04-09

Reporting Person: Brazzell Romulus K (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-09	Common Stock	M	1880	$0.68	Acquired	110605	Direct
2020-04-09	Common Stock	M	18247	$2.30	Acquired	128852	Direct
2020-04-09	Common Stock	M	47644	$3.34	Acquired	176496	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-09	Stock Option (right to buy)	$0.68	M	1880	Disposed	2023-05-09	Common Stock (1880)	Direct
2020-04-09	Stock Option (right to buy)	$2.30	M	18247	Disposed	2021-10-01	Common Stock (18247)	Direct
2020-04-09	Stock Option (right to buy)	$3.34	M	47644	Disposed	2026-06-16	Common Stock (47677)	Direct

Footnotes

F1: The option became fully vested on December 31, 2017.

F2: The option became fully vested on September 25, 2018.

F3: This option was granted on June 17, 2016 and vests over four years, with 25% of the shares underlying the option vesting on June 17, 2017 and an additional 2.0833% vesting at the end of each successive one-month period thereafter.